
Sign up to save your podcasts
Or


Episode Length: ~12–15 minutes Target Audience: Pain physicians, anesthesiologists, PM&R, sports medicine, and regenerative medicine clinicians Hosted by: Dr. David Rosenblum, MD Produced by: PainExam | NRAP Academy
🧠 Episode OverviewPeptides like BPC-157 have exploded in popularity across regenerative medicine, sports medicine, and cash-based pain practices — but does the science support the hype?
In this episode of PainExam, Dr. David Rosenblum takes a critical, evidence-based look at BPC-157 and other peptidesin pain management, examining:
The biological rationale behind peptide therapy
Preclinical and early human evidence for pain and tissue healing
Regulatory status and safety concerns
Ethical, legal, and marketing risks for physicians
How peptides are currently being incorporated — and monetized — in pain practices
This episode is designed to help clinicians separate science from marketing, and to approach peptide therapies with appropriate caution and professionalism.
⏱️ Episode Breakdown 🔹 00:00–01:30 — IntroductionWhy peptides are trending in pain and regenerative medicine
What patients are asking — and what physicians need to know
Origins of Body Protection Compound-157
Mechanisms: angiogenesis, inflammation modulation, tissue repair
Summary of preclinical data and animal pain models
Early inflammatory and non-inflammatory pain studies
Intra-articular BPC-157 for knee pain: what the case series showed
Why current human data are hypothesis-generating, not definitive
FDA status and investigational use
Quality, purity, and dosing variability
Theoretical biologic risks and drug interactions
How peptides are marketed in regenerative clinics
Cash-based models and patient demand
Ethical marketing, informed consent, and medicolegal exposure
Where peptides fit — and don't fit — in current pain practice
Why evidence still matters in regenerative medicine
BPC-157 shows promising preclinical data, but human evidence remains limited
Current studies lack randomization, controls, and long-term outcomes
Peptides are not FDA-approved for pain or musculoskeletal indications
Marketing peptides without transparency poses ethical and legal risk
Physicians must clearly distinguish experimental therapies from standard of care
Józwiak et al. Multifunctionality and Possible Medical Application of BPC-157 — MDPI Pharmaceuticals (2025)
McGuire et al. Regeneration or Risk? A Narrative Review of BPC-157 — Current Reviews in Musculoskeletal Medicine (2025)
Sikirić et al. Effects of BPC-157 on Inflammatory and Non-Inflammatory Pain — Inflammopharmacology (1993)
Lee & Padgett. Intra-Articular Injection of BPC-157 for Knee Pain — Alternative Therapies in Health and Medicine (2021)
If you're preparing for Pain Medicine boards or looking to strengthen your foundation in interventional and regenerative pain management, check out the educational resources at:
👉 https://www.nrappain.org
🎓 Offered through NRAP Academy:✅ PainExam® Pain Management Board Review
✅ ABA, ABPM, FIPP, and ABIPP exam preparation
✅ Ultrasound-guided pain procedure training
✅ Regenerative pain medicine education — grounded in evidence, not hype
✅ Virtual Pain Fellowship curriculum
All content is designed by practicing pain physicians, for practicing pain physicians.
🎯 Why Learn with NRAP Academy?Evidence-driven, board-relevant education
Practical clinical insights you can apply immediately
Trusted by physicians nationwide
Focused on ethical, safe, and effective pain care
👉 Explore courses and upcoming programs at https://www.nrappain.org
🎧 Subscribe & Stay SharpIf you found this episode helpful:
Subscribe to the PainExam Podcast
Share it with a colleague
Leave a review to help other pain physicians find evidence-based content
Disclaimer: This podcast is for educational purposes only. Discussion of investigational therapies does not constitute endorsement or clinical recommendation. Physicians should follow applicable laws, regulations, and professional guidelines when considering experimental treatments.
References
Lee, Edwin, and Blake Padgett. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Alternative Therapies in Health & Medicine 27.4 (2021).
Józwiak, Michalina, et al. "Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review." Pharmaceuticals 18.2 (2025): 185.
McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611-619.
By David Rosenblum, MD4.2
66 ratings
Episode Length: ~12–15 minutes Target Audience: Pain physicians, anesthesiologists, PM&R, sports medicine, and regenerative medicine clinicians Hosted by: Dr. David Rosenblum, MD Produced by: PainExam | NRAP Academy
🧠 Episode OverviewPeptides like BPC-157 have exploded in popularity across regenerative medicine, sports medicine, and cash-based pain practices — but does the science support the hype?
In this episode of PainExam, Dr. David Rosenblum takes a critical, evidence-based look at BPC-157 and other peptidesin pain management, examining:
The biological rationale behind peptide therapy
Preclinical and early human evidence for pain and tissue healing
Regulatory status and safety concerns
Ethical, legal, and marketing risks for physicians
How peptides are currently being incorporated — and monetized — in pain practices
This episode is designed to help clinicians separate science from marketing, and to approach peptide therapies with appropriate caution and professionalism.
⏱️ Episode Breakdown 🔹 00:00–01:30 — IntroductionWhy peptides are trending in pain and regenerative medicine
What patients are asking — and what physicians need to know
Origins of Body Protection Compound-157
Mechanisms: angiogenesis, inflammation modulation, tissue repair
Summary of preclinical data and animal pain models
Early inflammatory and non-inflammatory pain studies
Intra-articular BPC-157 for knee pain: what the case series showed
Why current human data are hypothesis-generating, not definitive
FDA status and investigational use
Quality, purity, and dosing variability
Theoretical biologic risks and drug interactions
How peptides are marketed in regenerative clinics
Cash-based models and patient demand
Ethical marketing, informed consent, and medicolegal exposure
Where peptides fit — and don't fit — in current pain practice
Why evidence still matters in regenerative medicine
BPC-157 shows promising preclinical data, but human evidence remains limited
Current studies lack randomization, controls, and long-term outcomes
Peptides are not FDA-approved for pain or musculoskeletal indications
Marketing peptides without transparency poses ethical and legal risk
Physicians must clearly distinguish experimental therapies from standard of care
Józwiak et al. Multifunctionality and Possible Medical Application of BPC-157 — MDPI Pharmaceuticals (2025)
McGuire et al. Regeneration or Risk? A Narrative Review of BPC-157 — Current Reviews in Musculoskeletal Medicine (2025)
Sikirić et al. Effects of BPC-157 on Inflammatory and Non-Inflammatory Pain — Inflammopharmacology (1993)
Lee & Padgett. Intra-Articular Injection of BPC-157 for Knee Pain — Alternative Therapies in Health and Medicine (2021)
If you're preparing for Pain Medicine boards or looking to strengthen your foundation in interventional and regenerative pain management, check out the educational resources at:
👉 https://www.nrappain.org
🎓 Offered through NRAP Academy:✅ PainExam® Pain Management Board Review
✅ ABA, ABPM, FIPP, and ABIPP exam preparation
✅ Ultrasound-guided pain procedure training
✅ Regenerative pain medicine education — grounded in evidence, not hype
✅ Virtual Pain Fellowship curriculum
All content is designed by practicing pain physicians, for practicing pain physicians.
🎯 Why Learn with NRAP Academy?Evidence-driven, board-relevant education
Practical clinical insights you can apply immediately
Trusted by physicians nationwide
Focused on ethical, safe, and effective pain care
👉 Explore courses and upcoming programs at https://www.nrappain.org
🎧 Subscribe & Stay SharpIf you found this episode helpful:
Subscribe to the PainExam Podcast
Share it with a colleague
Leave a review to help other pain physicians find evidence-based content
Disclaimer: This podcast is for educational purposes only. Discussion of investigational therapies does not constitute endorsement or clinical recommendation. Physicians should follow applicable laws, regulations, and professional guidelines when considering experimental treatments.
References
Lee, Edwin, and Blake Padgett. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Alternative Therapies in Health & Medicine 27.4 (2021).
Józwiak, Michalina, et al. "Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review." Pharmaceuticals 18.2 (2025): 185.
McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611-619.

3,382 Listeners

187 Listeners